A Vancouver-based research team led by Canada’s most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enough, a daily regimen of the non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen can prevent the onset of Alzheimer’s disease.
This means that by taking an over-the-counter medication, people can ward off a disease that, according to Alzheimer’s Disease International’s World Alzheimer Report 2016, affects an estimated 47 million people worldwide, costs health care systems worldwide more than US$818 billion  per year and is the fifth leading cause of death in those aged 65 or older.
The Alzheimer’s Association estimates that there are more than 5 million cases in the United States alone, with a new case being identified every 66 seconds. The annual cost to the country in 2017 is estimated have been US$259 billion, with that figure predicted to potentially rise to US$1.1 trillion  by 2050.
Dr. McGeer, who is President and CEO of Vancouver-based Aurin Biotech, and his wife, Dr. Edith McGeer, are among the most cited neuroscientists in the world. Their laboratory is world-renowned for their 30 years of work in neuroinflammation and neurodegenerative diseases, particularly Alzheimer’s disease. A paper detailing Dr. McGeer’s most recent discoveries has been published in the prestigious Journal of Alzheimer’s Disease.
In 2016, Dr. McGeer and his team announced that they had developed a simple saliva test that can diagnose Alzheimer’s disease, as well as predict its future onset. The test is based on measuring the concentration of the peptide amyloid-beta protein 42 (Abeta 42) secreted in saliva. In most individuals, the rate of Abeta 42 production is almost exactly the same regardless of sex or age. However, if that rate of production is two to three times higher, those individuals are destined to develop Alzheimer’s disease. That is because Abeta 42 is a relatively insoluble material, and although it is made everywhere in the body, deposits of it occur only in the brain, causing neuroinflammation, which destroys neurons in the brains of people with Alzheimer’s disease.
Contrary to the widely held belief that Abeta 42 is made only in the brain, Dr. McGeer’s team demonstrated that the peptide is made in all organs of the body and is secreted in saliva from the submandibular gland. As a result, with as little as one teaspoon of saliva, it is possible to predict whether an individual is destined to develop Alzheimer’s disease. This gives them an opportunity to begin taking early preventive measures such as consuming non-prescription non-steroidal drugs (NSAIDs) such as ibuprofen.
“What we’ve learned through our research is that people who are at risk of developing Alzheimer’s exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime,” says Dr. McGeer. “Knowing that the prevalence of clinical Alzheimer’s Disease commences at age 65, we recommend that people get tested ten years before, at age 55, when the onset of Alzheimer’s would typically begin. If they exhibit elevated Abeta 42 levels then, that is the time to begin taking daily ibuprofen to ward off the disease.
“Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal. Consequently, every therapeutic trial has failed to arrest the disease’s progression. Our discovery is a game changer. We now have a simple test that can indicate if a person is fated to develop Alzheimer’s disease long before it begins to develop. Individuals can prevent that from happening through a simple solution that requires no prescription or visit to a doctor. This is a true breakthrough since it points in a direction where AD can eventually be eliminated.”
The Latest on: Alzheimer’s disease
via Google News
The Latest on: Alzheimer’s disease
- Living near major roads linked to risk of dementia, Parkinson's, Alzheimer's and MSon January 23, 2020 at 11:36 am
Living near major roads or highways is linked to higher incidence of dementia, Parkinson's disease, Alzheimer's disease and multiple sclerosis (MS), suggests new research published this week in the ...
- Reelin can reverse the main pathological processes associated with Alzheimer's, other tauopathieson January 23, 2020 at 9:59 am
Alzheimer's disease is a neurodegenerative disease known for the loss of connection between neurons and neuronal death. It is largely linked to the creation of senile plaques (formed by the ...
- Missing O’Fallon, Missouri woman with Alzheimer’s found safeon January 23, 2020 at 8:47 am
Carole Politte, 77, was last seen at around noon on Wednesday. She said she was going shopping. Politte is 5-foot-7-inches tall, weighs 150 pounds and has gray hair and hazel eyes. She suffers from ...
- Reelin reverts the main pathological processes related to Alzheimer's and other tauopathyon January 23, 2020 at 8:34 am
Reelin, an essential protein for brain plasticity Alzheimer's disease is a neurodegenerative disease known for the loss of connection between neurons and neuronal death. It is largely linked to the ...
- How one NC museum program is using art to unlock memories in people with dementiaon January 23, 2020 at 8:01 am
Eleven of the 26 people in the two tour groups have Alzheimer’s disease or another dementia-related illness. The others are their caretakers. Reflections adds interactive sensory components to an art ...
- Drinking Coffee Might Lower Alzheimer’s Disease Riskon January 23, 2020 at 12:05 am
dementia or Alzheimer's disease. One of these online studies published in 2010 indicated three of the five studies it looked at agree coffee does have some positive effects on cognitive functioning. A ...
- How To Make A Difference In The Fight Against Alzheimer’son January 22, 2020 at 6:26 am
By Arnaud Bernaert, Head of Shaping the Future of Health and Health Care, World Economic Forum Alzheimer’s disease is uniquely devastating. It destroys a person’s memories and cognitive capabilities, ...
- Conference offers training for caregivers on Alzheimer's diseaseon January 21, 2020 at 8:40 am
Conference offers training for caregivers on Alzheimer's disease The conference brings together educators, trainers and experts to discuss topics that are important to family caregivers and healthcare ...
- Treatment of pain is a challenge in Alzheimer's diseaseon January 20, 2020 at 6:26 am
he treatment and management of pain in people with Alzheimer's disease (AD) can be a challenge due to problems in communication and uncommon symptoms of pain. Opioid painkillers are widely ...
via Bing News